Johnson & Johnson has reported new Phase 3 data demonstrating that the combination of TECVAYLI (teclistamab-cqyv) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) significantly outperformed standard treatments in patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy. The findings, disclosed during the 2025 American Society of Hematology Annual Meeting and published in The New England Journal of Medicine, showed an 83 percent reduction in the risk of disease progression or death compared to regimens based on pomalidomide or bortezomib. The combination has been granted Breakthrough Therapy Designation by the United States Food and Drug Administration and is currently under Real-Time Oncology Review.

Why the MajesTEC-3 trial represents a clinical turning point

The MajesTEC-3 trial introduces a major inflection point in the treatment paradigm for multiple myeloma. It is the first randomized Phase 3 study to demonstrate that a bispecific antibody regimen not only improves progression-free survival but also shows a statistically significant overall survival advantage as early as second-line therapy. The study enrolled patients with a limited treatment history, a population that is more representative of typical community oncology settings compared to late-line studies that often focus on triple-class refractory patients.

The comparator arms included standard-of-care options such as DARZALEX FASPRO plus dexamethasone with either pomalidomide (DPd) or bortezomib (DVd). These combinations reflect widely adopted clinical practices and lend external validity to the trial’s findings. The hazard ratio for progression-free survival was 0.17, while overall survival also favored the investigational combination with a hazard ratio of 0.46. These findings are notable not only for their magnitude but also for the long-term follow-up, which extended to nearly three years.

How the mechanism of action elevates this combination

The immunologic rationale behind combining TECVAYLI and DARZALEX FASPRO lies in their complementary targeting of BCMA and CD38. TECVAYLI is a bispecific T-cell engager that activates T-cells by binding to CD3 and simultaneously targeting B-cell maturation antigen on myeloma cells. DARZALEX FASPRO, already well-established as a CD38-directed monoclonal antibody, enhances this approach by depleting immunosuppressive cells and further priming the tumor microenvironment.

This dual-targeting strategy appears to create a more sustained and potent T-cell response compared to monotherapies or less synergistic combinations. The high rates of minimal residual disease negativity and complete response observed in the trial suggest not just deeper responses, but also more durable disease control, which could meaningfully delay the need for subsequent lines of therapy or stem cell transplantation.

Why the safety profile could be manageable in real-world use

While bispecifics are often associated with challenging safety profiles, the MajesTEC-3 data offer some reassurance. The incidence of Grade 3 or 4 treatment-emergent adverse events was similar between the combination and the control arms, with the majority attributed to infections and cytopenias. Although 60 percent of patients experienced cytokine release syndrome, all cases were Grade 1 or 2 and managed effectively with standard protocols. Notably, infections declined after the initial six-month treatment window, aided by immunoglobulin supplementation, prophylactic antibiotics, and a shift to monthly maintenance dosing.

Discontinuations due to adverse events were low, at under five percent in both arms. Immune effector cell-associated neurotoxicity was rare, occurring in just over one percent of patients. These findings support the feasibility of using this combination in outpatient settings, particularly for patients who are not eligible for high-intensity regimens or stem cell transplantation.

What this could change in second-line treatment selection

The most immediate impact of the MajesTEC-3 data is the potential displacement of existing second-line options such as pomalidomide- and bortezomib-based regimens. If the United States Food and Drug Administration grants full approval, TECVAYLI plus DARZALEX FASPRO could become the preferred option for patients who have failed one prior therapy, particularly those who may benefit from a steroid-sparing regimen or who prefer subcutaneous administration over oral agents with more complex toxicity profiles.

Unlike CAR-T therapies that require leukapheresis and lengthy manufacturing timelines, TECVAYLI is an off-the-shelf product that allows for more flexible scheduling and faster treatment initiation. Its administration on a DARZALEX-compatible schedule also reduces patient burden and enhances operational compatibility within existing infusion workflows. Industry observers note that this could facilitate broader uptake in community oncology practices where infrastructure for cellular therapies remains limited.

What reimbursement, access, and implementation challenges remain

Despite its clinical appeal, the combination therapy will face a steep climb on the reimbursement front. Bispecifics are expensive to manufacture and distribute, and combining two high-cost agents could trigger payer scrutiny, especially if long-term maintenance is required. Health technology assessment bodies in Europe may request additional pharmacoeconomic modeling and post-marketing data before recommending widespread coverage. In the United States, managed care plans will likely demand clear documentation of superiority over generic regimens, particularly in patients with comorbidities who may not tolerate full-dose treatment.

The need for infection prophylaxis, immunoglobulin support, and ongoing monitoring for immune-related adverse events also creates operational friction that could limit adoption in under-resourced settings. Clinicians will need to carefully evaluate whether patients can be monitored adequately in outpatient infusion centers or if referral to specialty centers is warranted.

What signals regulators are sending through expedited review

The Breakthrough Therapy Designation and Real-Time Oncology Review pathway indicate a strong signal from the United States Food and Drug Administration regarding the unmet need in earlier-line multiple myeloma treatment. The agency’s decision to initiate review before the formal submission of the supplemental Biologics License Application suggests confidence in both the dataset and the regulatory precedent set by prior TECVAYLI approvals.

Johnson & Johnson has also filed for regulatory review in Brazil, and additional filings in Europe and Asia are expected. The company’s established manufacturing and commercial infrastructure for both TECVAYLI and DARZALEX FASPRO may further accelerate global launch timelines if approvals are granted in major markets.

What the field is likely to watch next

The next frontier for this combination lies in defining optimal treatment duration and sequencing. It remains unclear whether patients achieving a complete response can safely discontinue therapy or shift to reduced dosing frequencies without risking relapse. Further analysis of long-term quality-of-life metrics, patient-reported outcomes, and real-world adherence data will be critical in guiding clinical guidelines and reimbursement policy.

Additional data from the broader MajesTEC program may also inform whether similar bispecific combinations can be used in earlier settings, including newly diagnosed patients or those with high-risk cytogenetics. Clinicians are also watching for signals about whether TECVAYLI can be safely combined with other immunotherapies, such as checkpoint inhibitors or novel T-cell engagers targeting antigens beyond BCMA.

  bispecific antibodies, daratumumab, DARZALEX FASPRO, FDA, immunotherapy, Johnson & Johnson, oncology trials, Phase 3 MajesTEC-3, Real-Time Oncology Review, relapsed/refractory multiple myeloma, teclistamab, TECVAYLI